In March 2022, FDA approved Opdualag, i.e., a combination of immune checkpoint inhibitors, Nivolumab & Relatlimab-rmbw, for patients aged 12 years or older with unresectable or metastatic melanoma. Both drugs block proteins on immune cells, which, in turn, releases the immune response against cancer cells.
▶️ 𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐭𝐡𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐟𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬: - https://lnkd.in/dQxvbzmw
#malignant_melanoma_market #tumour #cancer #allergies #melanoma #biopsy #drugs #healthcare #marketresearch #marknteladvisors
Like
Comment
Share
1 (877) 773-1002